Positive high-level results from the phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualised rate of ...

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...

Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the a ...

The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or ...

WILMINGTON, Del. - AstraZeneca (LSE/STO/NYSE:AZN) reported positive results from two Phase III clinical trials showing its experimental drug tozorakimab reduced moderate-to-severe exacerbations in ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...

Sanofi’s lunsekimig met its endpoints in asthma and CRSwNP but missed the primary endpoint in eczema.

Bristol Myers Squibb is adding three prescription medications on TrumpRx.gov on Monday, offering discounts of up to 90%, FOX Business has learned.

The best ways to get rid of phlegm, from using nasal sprays to taking the right OTC medications. Plus, they explain what ...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Lunsekimig is one of a trio of clinical candidates that Sanofi is developing as successors to its big-selling IL-3 and IL-13 ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...